Skip to main content
. Author manuscript; available in PMC: 2021 Jul 17.
Published in final edited form as: Curr Opin Cell Biol. 2016 Feb 27;39:69–76. doi: 10.1016/j.ceb.2016.02.009

Table 1. Genes and pharmacological agents that alter the subcellular localization of lysosomes.

Treatment Lysosomal localization LMP Physiological effect References
ErbB1/2 inhibition (Lapatinib) ERBB2 RNAi CTSB/CTSL RNAi Perinuclear ND Attenuated invasion [21,22]
Cationic amphiphilic drugs Siramesine Perinuclear ND + Expansion of lysosomal compartment [67]; Unpublished observations
BORCS5 (BORC complex protein) KO, ARL8B RNAi Perinuclear ND Reduced cell adhesion and motility, Lysosome traffic [17,27]
KIF2A, KIF1B RNAi, Starvation Perinuclear ND mTORC activation, autophagy modulation [10]
KIF20A, KIF25 RNAi, KIF5B RNAi Peripheral/protrusions + Accumulation of autophagosomes [57,68]
DHC, Htt RNAi, RUFY1, δ-adaptin RNAi Peripheral/protrusions ND Exaggerated protrusions, Lysosomal detachment from MTs [32,33]
RAB7 shRNA ND ND Hydrolase secretion, increased invasion [69]
TPM2, MYH1 RNAi Peripheral/protrusions + Cell death [57]
TMEM106b shRNA Peripheral + Increased lysosomal axonal motility [16]
Cambinol (HDAC inhibitor), Troglizatone (PPARγ agonist), EIPA, (sodium-proton exchanger inhibitor) Perinuclear ND Attenuated invasion [28,31], Dykes et al, 2015